Arix Bioscience is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks needed to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors

Differentiated proposition

Biotech ventures for public markets

Arix provides public market investors access to game changing life science innovation across a range of therapeutic areas and geographies

Flexible long term capital

Our plc balance sheet enables us to take a longer term view than our non listed peers. We can provide companies with the flexible, long term capital they require to grow

Hands on support

We provide more than just capital when we invest. We take a board seat and play and active role to support our companies grow. We provide scientific and commercial experience to help navigate clinical and operational hurdles.

Pharma partners

Partnerships with Fosun, Takeda, UCB and Ipsen provide access to extensive R&D insights and due diligence capabilities

Extensive global networks

Premium access to innovation through transatlantic team and high quality, global venture capital, biotech and academic networks

Unconstrained model

Unconstrained by institution, geography or stage of company development; ability to source the best life science innovation without restriction

Global Reach

Our global network and transatlantic team provide us with access to a large pool of opportunities, wide scientific networks and a deep understanding of the industries and markets in which we invest.
Academic and Pharmaceutical partnerships provide access to extensive R&D insights and due diligence capabilities. Through these networks we can provide portfolio companies with the additional, capital, expertise and networks they need to become global leaders.

+ Expand geographic breakdown

Portfolio companies

San Diego, CA, US

Cambridge, UK

Ness Ziona, Israel

Cambridge, MA, US

London, UK

Paris, France

San Francisco, CA, US

Cambridge, MA

Dublin, Ireland

Cambridge, MA, US

Ness Ziona, Israel

Cleveland, OH, US

Frenchs Forest , NSW, Australia

Montreal, Canada

San Diego, CA, US

London, UK

Pharma partners

Shanghai, China

Paris, France

Tokyo, Japan

Brussels, Belgium

Research accelerators

Cleveland, Ohio, US

Dortmund, Germany

Business Model

Our primary business objective is to focus on the sourcing, financing and development of innovative technologies

Exit

We will exit when the optimum value has been reached
Capital is recycled onto the balance sheet to be reinvested in new opportunities, creating a sustainable model for the future

Develop

We take a hands-on approach when we invest, positioning our companies for growth and clinical success. Our portfolio companies get access to our global networks and partners and the flexible, long term capital they need to grow
We have the experience to navigate scientific and commercial hurdles, mitigating risk for our shareholders

Discover

Unconstrained approach; ability to source the best life science innovation without restriction
Extensive global networks and partnerships enable easy access to the most innovative biotech entrepreneurs

Evaluate

Thorough due diligence to evaluate scientific and commercial opportunity for both new and follow-on investments
Access to extensive R&D resources and due diligence capabilities at pharmaceutical partners
Invest in breakthrough science innovation with a clear commercial pathway

Invest

Flexible on point of entry, geography and therapeutic area
Tend to be a lead investor
Plc balance sheet allows us to support companies through all stages of growth

How We Source

Arix has developed a wide network that includes research accelerators, universities and pharma companies. Through this network, Arix is able to identify new technologies and discoveries that provide a rich pipeline of potential investments.

Pharmaceutical partnerships

Pharmaceutical partnerships

Academic and research

Academic and research

Biotech networks

Biotech networks

Venture capital networks

Venture capital networks